• Biovica highlighted new clinical data supporting DiviTum TKa as a decision-support tool in metastatic breast cancer; results were already presented during the period.
• Additional evidence in immunotherapy settings was already presented at AACR, reinforcing the test’s potential role in treatment monitoring.
• Subsequent data were presented at ESMO Breast Cancer 2026, extending relevance across multiple treatment settings.
• New Phase III data released after fiscal 2025/26 end showed DiviTum TKa captured treatment-specific biological response, supporting broader clinical and drug-development uptake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.